Advertisement
Advertisement
SVRA
Savara Inc.
5.23
USDSponsored
+0.07
+1.36%
May 08, 16:00 UTC -4
Closed
Pre-Market
5.14
-0.09
-1.63%
SVRA Earnings Reports
Positive Surprise Ratio
SVRA beat 23 of 40 last estimates.
57%
Next Report
Date of Next Report
Aug 11, 2026
Estimate for Q2 26 (Revenue/ EPS)
--
/-$0.13
Implied change from Q1 26 (Revenue/ EPS)
--
/--
Implied change from Q2 25 (Revenue/ EPS)
--
/-7.14%
Savara Inc. earnings per share and revenue
On May 07, 2026, SVRA reported earnings of -- USD per share (EPS) for Q1 26, -- the estimate of -0.13 USD, resulting in a --% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +1.36% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 8 analysts forecast an EPS of -0.13 USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Amylyx Pharmaceuticals, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.33
Actual
-$0.37
Surprise
-9.82%
Collegium Pharmaceutical, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
$1.62
Actual
$1.76
Surprise
+8.43%
4D Molecular Therapeutics, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$1.01
Actual
-$1.01
Surprise
+0.21%
Akebia Therapeutics, Inc.
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.02
Actual
-$0.03
Surprise
-4.90%
Organogenesis Holdings Inc. Class A Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.31
Actual
-$0.37
Surprise
-17.01%
OmniAb, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.10
Actual
-$0.06
Surprise
+41.18%
Stevanato Group S.p.A.
Report Date
May 07, 2026 For Q1 26
Estimate
$0.10
Actual
$0.11
Surprise
+5.45%
Crinetics Pharmaceuticals, Inc.
Report Date
May 07, 2026 For Q1 26
Estimate
-$1.26
Actual
-$1.23
Surprise
+2.51%
Nektar Therapeutics
Report Date
May 07, 2026 For Q1 26
Estimate
-$1.62
Actual
-$1.82
Surprise
-11.88%
Definium Therapeutics, Inc. Common Shares
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.50
Actual
-$0.71
Surprise
-41.43%
FAQ
What were Savara Inc.'s earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Savara Inc. reported EPS of --, missing estimates by --, and revenue of --, 0% as expectations.
How did the market react to Savara Inc.'s Q1 2026 earnings?
The stock price moved up 1.36%, changed from $5.16 before the earnings release to $5.23 the day after.
When is Savara Inc. expected to report next?
The next earning report is scheduled for Aug 11, 2026.
What are the forecasts for Savara Inc.'s next earnings report?
Based on 8
analysts, Savara Inc. is expected to report EPS of -$0.13 and revenue of -- for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement